modelTemozolomide
Extends from Pharmacolibrary.Drugs.ATC.L.L01AX03.
Information
| name: | Temozolomide | |
| ATC code: | L01AX03 | route: | oral |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 0.4 | L |
| clearance: | 2.5 | L/h/m2 |
| other parameters in model implementation | ||
Temozolomide is an oral alkylating agent, primarily used in the treatment of certain brain tumors such as glioblastoma multiforme and anaplastic astrocytoma. It is approved for use in many countries and is considered a standard of care for high-grade gliomas.
Pharmacokinetics
Pharmacokinetic parameters reported for adult cancer patients (glioblastoma), mixed sexes, typical age range 18-70 years, normal renal and hepatic function.
References
Singh, R, et al., & Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer chemotherapy and pharmacology 83(2) 319–328. DOI:10.1007/s00280-018-3731-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30456480
Büsker, S, et al., & Peyrl, A (2022). Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. Cancer chemotherapy and pharmacology 89(5) 617–627. DOI:10.1007/s00280-022-04424-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35355137
Panetta, JC, et al., & Stewart, CF (2003). Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer chemotherapy and pharmacology 52(6) 435–441. DOI:10.1007/s00280-003-0670-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/13680158
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)